We predict syndromic multiplex testing will eventually displace most tests for individual pathogens. Not right away of course, but inevitably over the next decade or more.

The incremental cost (cost, not price) of a multiplex assay will be equal to a singleplex assay and this implies the end of singleplex in routine use. This is a significant beginning of a much larger trend where increasingly the physician’s role in diagnosis is displaced by more efficient and accurate technology. The value of physician time is not effectively costed in most medical systems and generally not in In Vitro Diagnostics where tests are viewed as a controllable cost and physicians are viewed as culprits in the ordering of unnecessary tests. The fact is this technology is far more accurate, and efficient than any physician could be.

Read the full situation analysis in the latest edition of our syndromic multiplex diagnostics market report https://lnkd.in/evUkq3jj